keyword
https://read.qxmd.com/read/38280503/oral-anticoagulation-for-hemodialysis-patients-with-atrial-fibrillation-the-therapeutic-conundrum-remains
#21
EDITORIAL
John D Horowitz, Natasha M Rogers
No abstract text is available yet for this article.
January 25, 2024: Trends in Cardiovascular Medicine
https://read.qxmd.com/read/38272779/factor-xi-inhibitors-potential-role-in-end-stage-kidney-disease
#22
REVIEW
Matthew Ades, Camille Simard, Thomas Vanassche, Peter Verhamme, John Eikelboom, Thomas A Mavrakanas
Patients with end-stage kidney disease (ESKD) experience a high thrombotic risk but are also at increased risk of bleeding. There is an unmet need for safer antithrombotic therapy in patients with ESKD on hemodialysis. Factor XI (FXI) represents an attractive therapeutic target for anticoagulation because of the potential to mitigate the bleeding risks associated with currently approved anticoagulants, especially in patients at high risk of bleeding. FXI inhibition is also an attractive option in settings where coagulation is activated by exposure of the blood to artificial surfaces, including the extracorporeal circuit during hemodialysis...
January 24, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38272778/how-to-ensure-patency-of-the-extracorporeal-circuit-in-hemodialysis-global-perspectives
#23
REVIEW
Alba Santos, Almudena Vega, Andrew Davenport
An adequate knowledge of anticoagulants used to prevent clotting in the extracorporeal circuit is crucial to provide optimal hemodialysis. Drugs can potentially prevent extracorporeal circuit clotting, but administration, half-life, and potential side effects differ. However, there is a lack of concise recommendations to guide anticoagulation and to avoid side effects. Because of the development of newer anticoagulant agents, direct thrombin inhibitors, and heparinoids, some of the side effects related to heparin may be overcome, but a deeper knowledge of these newer drugs is necessary...
January 24, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38267348/detection-and-scoring-of-extracorporeal-circuit-clotting-during-hemodialysis
#24
REVIEW
Floris Vanommeslaeghe, Wim Van Biesen, Karlien François
Maintaining patency of the extracorporeal hemodialysis (HD) circuit is a prerequisite to perform HD. Unfractionated heparin and low-molecular-weight heparins are the most used anticoagulants in maintenance HD, but their administration comes with a major trade-off of bleeding complications. This narrative review article discusses technical factors impacting on HD circuit patency, such as tubings, dialyzer membranes, priming practices, and treatment settings. Strategies for monitoring extracorporeal circuit clotting during and after treatment are also reviewed, as these are essential tools for optimizing anticoagulation...
January 23, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38262850/clotting-propensity-of-surface-treated-membranes-in-a-hemodialysis-set-up-that-avoids-systemic-anticoagulation
#25
REVIEW
Hideki Kawanishi, Masahide Koremoto, Casper F M Franssen, Marco van Londen
The development of biocompatible membranes, aiming to limit the inflammatory response, oxidative stress, and coagulability during hemodialysis, has been an important step in reducing dialysis-related adverse outcomes. This includes a reduction in the risk of clotting of the extracorporeal circuit, thus enabling hemodialysis with a reduced dose or even without systemic anticoagulant drugs in patients with an increased bleeding risk. In this article, we summarize the in vitro research and clinical evidence on the antithrombotic properties of vitamin E- and heparin-coated membranes...
January 22, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38256404/cardiovascular-events-and-mortality-in-patients-on-hemodialysis-the-prognostic-value-of-the-cha-2-ds-2-vasc-score
#26
JOURNAL ARTICLE
Theodoros Tourountzis, Georgios Lioulios, Fotini Stasini, Zoi Skarlatou, Stamatia Stai, Michalis Christodoulou, Eleni Moysidou, Evdoxia Ginikopoulou, Maria Stangou
Background and Objectives : Cardiovascular events are the major cause of morbidity and mortality in patients on hemodialysis (HD). Identifying risk factors can help in the effort to reduce cardiovascular risk and improve life expectancy. The objective of this study was to evaluate the ability of the CHA2 DS2 -VASc score-the risk index of stroke in atrial fibrillation (AF)-to predict strokes, major cardiovascular events, and mortality in patients with end-stage kidney disease. Materials and Methods : The CHA2 DS2 -VASc and HAS-BLED scores (the bleeding risk from the use of anticoagulation in AF) were calculated in 237 HD patients, 99 women with a median age of 76 (15) years, at the time they commenced HD...
January 12, 2024: Medicina
https://read.qxmd.com/read/38238225/bleeding-risk-in-hemodialysis-patients
#27
REVIEW
Anita van Eck van der Sluijs, Pearl Pai, Wenjuan Zhu, Gurbey Ocak
Cardiovascular diseases are highly prevalent among patients on dialysis. For these diseases, antiplatelets and antithrombotic therapies including heparin, vitamin K antagonists, and direct oral anticoagulants, are being used. However, the benefit-risk balance of these therapies could differ for dialysis patients compared with the general population. This review article focuses on the bleeding risk associated with the use of heparin, antiplatelets, vitamin K antagonists, and direct oral anticoagulants in patients receiving hemodialysis...
January 17, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38236118/heparin-induced-thrombocytopenia-syndrome-among-hemodialysis-patients-and-disease-management-strategy
#28
JOURNAL ARTICLE
Q Qasim
The objective of this study is to investigate the impact of heparin-induced thrombocytopenia syndrome on individuals undergoing hemodialysis. Heparin-induced thrombocytopenia in hemodialysis patients (HD-HIT) is a condition believed to occur in hemodialysis patients who experience a sudden decrease in platelet count or unexplained blood clotting, particularly when there is evidence of thrombosis in the dialysis circuit despite adequate heparin dosage. HD-HIT is thought to be caused by a drug reaction and hyper immunoglobulin syndrome...
November 2023: Georgian Medical News
https://read.qxmd.com/read/38233291/clotting-of-the-extracorporeal-circuit-in-hemodialysis-beyond-contact-activated-coagulation
#29
REVIEW
Matthias M Engelen, Peter Verhamme, Thomas Vanassche
Thrombotic complications in patients with end-stage kidney disease are frequent. While being a lifesaving treatment for these patients, hemodialysis introduces a thromboinflammatory environment. Additionally, the extracorporeal hemodialysis circuit itself is prone to clotting because of an interaction between different activation mechanisms of the coagulation system, platelets, and the immune system. Anticoagulation of the patient and the machine is frequently complicated by bleeding. We discuss the factors important in this balancing act and touch on potential strategies that are on the horizon to target thromboinflammation...
January 16, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38233290/patient-perspectives-on-clotting-in-the-extracorporeal-circuit-and-decision-making-regarding-anticoagulation-therapy
#30
REVIEW
Chandana Guha, Daniel Gallego, Amanda Grandinetti, Madeleine Warren, Allison Jaure
Clotting of the extracorporeal circuit is a complication in the process of hemodialysis that can result in missed or shortened dialysis sessions, higher nursing workload, and elevated cost of treatment. Repercussions of inadequate dialysis may include patient blood loss, fluid overload, build-up of minerals, higher hospitalization rates, and poor quality of life, contributing to increased patient distress. Preventing clotting through anticoagulation therapy is the key to maintaining patency of the dialysis circuit and supporting dialysis adequacy...
January 16, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38231233/clearance-and-nutrition-in-neonatal-continuous-kidney-replacement-therapy-using-the-carpediem%C3%A2-system
#31
JOURNAL ARTICLE
Kim T Vuong, Molly R Vega, Lauren Casey, Sarah J Swartz, Poyyapakkam Srivaths, Scott W Osborne, Christopher J Rhee, Ayse Akcan Arikan, Catherine Joseph
BACKGROUND: Infants with kidney failure (KF) demonstrate poor growth partly due to obligate fluid and protein restrictions. Delivery of liberalized nutrition on continuous kidney replacement therapy (CKRT) is impacted by clinical instability, technical dialysis challenges, solute clearance, and nitrogen balance. We analyzed delivered nutrition and growth in infants receiving CKRT with the Cardio-Renal, Pediatric Dialysis Emergency Machine (Carpediem™). METHODS: Single-center observational study of infants receiving CKRT with the Carpediem™ between June 1 and December 31, 2021...
January 17, 2024: Pediatric Nephrology
https://read.qxmd.com/read/38226554/efficacy-and-safety-of-apixaban-for-the-prevention-of-thrombosis-in-arteriovenous-grafts
#32
JOURNAL ARTICLE
Arash Hedayat, Aidin Esrafilian Soltani, Mahdi Hakiminezhad, Fateme Zareian, Mandana Saneian, Mohamad Moradmand, Sahand Abrishami, Mohamad Hosein Tabatabaei Nodoushan, Ali Pouriayevali, Mahdi Mohebbi, Helia Ghorbani
This research aims to fill a vital gap in existing studies by evaluating the efficacy and safety of Apixaban, a direct oral anticoagulant, in the prevention of arteriovenous graft (AVG) thrombosis, thereby offering substantial insights into alternative anticoagulant options for hemodialysis patients. Conducted as a multi-center, randomized, double-blind, placebo-controlled trial, this study involved end-stage renal disease (ESRD) patients who had recently received polytetrafluoroethylene grafts. Participants were assigned to receive either Apixaban at a dose of 2...
January 15, 2024: European Journal of Translational Myology
https://read.qxmd.com/read/38220473/avoiding-systemic-heparinization-during-hemodialysis-how-the-dialysis-setup-might-help
#33
REVIEW
Florine V Janssens, Björn Meijers, Karlien François
Heparin is the most widely used anticoagulant for maintaining patency of the extracorporeal blood circuit during intermittent hemodialysis. Inadvertently, this leads to systemic heparinization of the patient. Repeated intermittent heparinization during hemodialysis has been associated with increased bleeding risks and metabolic and immunologic effects. Alternative strategies for minimizing systemic anticoagulation encompass dilution methods, regional citrate anticoagulation, priming of the extracorporeal circuit, and modifications to dialyzer membranes and dialysate composition...
January 13, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38212212/regional-citrate-anticoagulation-a-tale-of-more-than-two-stories
#34
REVIEW
Thomas Demuynck, Muriel Grooteman, Piet Ter Wee, Mario Cozzolino, Björn Meijers
Calcium is a key clotting factor, and several inorganic molecules that bind to calcium have been found to reduce the clotting propensity of blood. Citrate, a calcium chelator, is used as inhibitor of the coagulation cascade in blood transfusion. Also, it is used as an anaticoagulant during dialysis to maintain patency of the extracorporeal circuit, known as regional citrate anticoagulation (RCA). The amount of citrate should be chosen such that ionized calcium concentrations in the extracorporeal circuit are reduced enough to minimize propagation of the coagulation cascade...
January 10, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38199825/anticoagulation-for-hemodialysis-a-hidden-quest-to-ensure-safe-dialysis
#35
EDITORIAL
Karlien François, Björn Meijers
No abstract text is available yet for this article.
January 10, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38195305/lipid-and-bone-effects-of-heparin-use-during-hemodialysis
#36
REVIEW
Bernd Stegmayr, Li Zuo, Ward Zadora
Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) are commonly prescribed anticoagulants for chronic hemodialysis (HD). The dialysis population comprises a unique group that receives heparin three times per week for a long period, with potential long-term cumulative metabolic effects such as osteoporosis and worsening lipid profile. HD patients have approximately half the number of lipases as healthy individuals, and their lipid metabolism is limited because of this decrease as well as partially inhibited function...
January 8, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38195304/immunologic-effects-of-heparin-associated-with-hemodialysis-focus-on-heparin-induced-thrombocytopenia
#37
REVIEW
Theodore E Warkentin
Intermittent hemodialysis (HD) is almost invariably performed with heparin, and thus HD patients are at risk of developing the immune-mediated adverse effect heparin-induced thrombocytopenia (HIT), caused by anti-platelet factor 4/heparin IgG, which strongly activates platelets. HIT patients develop hypercoagulability with greatly increased risk of thrombosis, both venous and arterial. Certain HIT-associated complications are more likely to develop among HD patients, including hemofilter thrombosis despite heparin, intravascular catheter and/or arteriovenous fistula-associated thrombosis, post-heparin bolus anaphylactoid/anaphylactic reactions, and thrombotic stroke and acute limb artery thrombosis (reflecting the high frequency of underlying arteriopathy in many patients with renal failure)...
January 8, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38189095/comparison-of-citrate-dialysate-in-pre-and-post-dilution-online-hemodiafiltration-effect-on-clot-formation-and-adequacy-of-dialysis-in-hemodialysis-patients
#38
JOURNAL ARTICLE
Pasu Nakornchai, Arisara Jitraree, Monpinya Charttong Homjan, Thanachit Laykhram, Thananda Trakarnvanich
BACKGROUND: Citrate dialysate (CD) has been successfully used in conventional hemodialysis and continuous renal replacement therapy; however, no study has compared pre- and post-dilution online hemodiafiltration (oL-HDF). Therefore, we aimed to investigate the efficacy of citrate anticoagulation for oL-HDF and the metabolic changes and quality of life of patients on hemodialysis treated using both modes. METHOD: Eight dialysis patients were treated with CD containing 0...
December 2024: Renal Failure
https://read.qxmd.com/read/38166439/fatal-superior-vena-cava-rupture-complicating-dialysis-catheter-exchange
#39
JOURNAL ARTICLE
Ahmed E Ali, Alian Al-Balas, Paul V Benson, Ammar Almehmi
Central vein stenosis (CVS) is a common and challenging complication in hemodialysis patients with chronic central venous catheters (CVCs). CVS often remains asymptomatic and is discovered incidentally during follow-up imaging. CVS symptoms include arm swelling, venous hypertension, impaired dialysis flow rates, and development of collateral veins. However, these symptoms can be nonspecific and overlap with other conditions, making the diagnosis challenging. Timely recognition and appropriate intervention are crucial to prevent complications and optimize patient outcomes...
January 2, 2024: Journal of Vascular Access
https://read.qxmd.com/read/38157764/construction-and-study-of-blood-purification-membrane-modified-with-pde-inhibitor-investigation-of-antiplatelet-activity-and-hemocompatibility
#40
JOURNAL ARTICLE
Xiao Fu, Ting Lei, Cong Chen, Gan Fu
The recent "cell-based theory" of coagulation suggests that platelets serve as the site of coagulation factor reactions, making platelets an effective target for inhibiting membrane thrombosis. Unfortunately, there is limited research on how blood purification membranes affect platelet intracellular signaling. In this study, we modified polyethersulfone (PES) membranes with the platelet phosphodiesterase (PDE) inhibitor dipyridamole (DIP) and investigated the effects of the DIP/PES (DP) membranes on platelet adhesion, activation, aggregation, and secretion, as well as the role of the PDE-cyclic adenosine monophosphate (cAMP) intracellular signaling pathway...
December 24, 2023: Colloids and Surfaces. B, Biointerfaces
keyword
keyword
119301
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.